Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 1-Year Low – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) hit a new 52-week low during trading on Friday . The stock traded as low as $19.50 and last traded at $20.05, with a volume of 461594 shares traded. The stock had previously closed at $25.06.

Chugai Pharmaceutical Trading Up 2.6%

The company’s 50 day moving average is $24.72 and its 200-day moving average is $24.68. The company has a market capitalization of $67.70 billion, a P/E ratio of 26.04 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 EPS for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The company had revenue of $2.01 billion for the quarter. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.